Manisha Moorjani

This inventor holds 25 USPTO granted patents and 7 published patent applications, plus 8 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Celgene International Ii Sarl, Receptos, Inc., Neurocrine Biosciences, Inc.. Active years: 2010-2021.

USPTO Granted Patents = 25 (Patent Applications = 7)

% Patents Active = 84.0

CIPO Patents = 8 (Patent Applications = 2)

EPO Patents = 13 (Patent Applications = 14)

Average Co-Inventor Count = 7.7

ph-index = 7

Forward Citations = 106(Granted Patents)

Company Filing History:

10 out of 17

Celgene International Ii Sarl

Neurocrine Biosciences, Inc.

where one patent can have more than one assignee

Years Active: 2010-2021

Loading Chart...

Areas of Expertise:

GLP-1 Receptor Modulators

Sphingosine 1 Phosphate Receptor Modulators

Substituted Triazoles

Chiral Synthesis

Heterocyclic Compounds

Receptor Stabilizers

Pharmaceutical Formulations

CRF Receptor Antagonists

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11021449 - Substituted triazoles and methods relating thereto (2021-06-01),

2. 10738017 - Substituted triazoles and methods relating thereto (2020-08-11),

3. 10259823 - GLP-1 receptor modulators (2019-04-16),

4. 10239846 - Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis (2019-03-26),

5. 10138214 - Substituted triazoles and methods relating thereto (2018-11-27),

6. 10034886 - GLP-1 receptor modulators (2018-07-31),

7. 9839664 - GLP-1 receptor modulators (2017-12-12),

8. 9795613 - GLP-1 receptor modulators (2017-10-24),

9. 9718789 - Substituted triazoles and methods relating thereto (2017-08-01),

10. 9700543 - GLP-1 receptor stabilizers and modulators (2017-07-11),

11. 9598430 - GLP-1 receptor modulators (2017-03-21),

12. 9481659 - Selective heterocyclic sphingosine 1 phosphate receptor modulators (2016-11-01),

13. 9474755 - GLP-1 receptor modulators (2016-10-25),

14. 9394264 - Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis (2016-07-19),

15. 9388147 - Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis (2016-07-12),

Title: The Innovations of Manisha Moorjani: A Pioneer in Neurological Treatments

Introduction

Manisha Moorjani, located in San Diego, CA, is an inventive mind who has made significant contributions to the field of neurological health. With an impressive portfolio of 25 patents, her innovative work focuses primarily on the development of therapeutic compounds aimed at treating a variety of neurological disorders.

Latest Patents

Moorjani's latest patents include groundbreaking work on substituted triazoles, specifically substituted 1,2,3-triazole compounds. These compounds are designed for utility in the treatment of diverse neurological disorders. The patents detail the general structure of these compounds, which encompasses their stereoisomers, esters, solvates, and pharmaceutically acceptable salts. Furthermore, these patents include formulations that combine these triazole compounds with a pharmaceutically acceptable carrier, outlining methods for their use in treating patients afflicted with neurological issues.

Career Highlights

Throughout her career, Moorjani has worked with notable companies such as Receptos, Inc., and Celgene International II Sàrl. Her experience in these organizations has shaped her understanding of the pharmaceutical industry and deepened her expertise in the development of innovative treatments.

Collaborations

Moorjani's efforts have been bolstered by collaborations with distinguished colleagues such as Marcus F. Boehm and Esther Martinborough. These partnerships have facilitated important research and development initiatives that push the boundaries of neurological therapies.

Conclusion

Manisha Moorjani’s innovative contributions to the field of neurological treatment through her patents and collaborative efforts highlight her as a leading figure in medical research. Her work not only represents advancements in scientific understanding but also holds promise for enhancing the quality of life for individuals suffering from neurological disorders.